{"analyses":[{"ciLowerLimit":"0.296","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.485","estimateComment":"Stratified analysis:Strata were chemotherapy selected (paclitaxel, PLD, or topotecan), prior anti-angiogenic therapy (yes or no), and platinum-free interval (less than \\[\\<\\] 3 or 3-6 months). Cox regression model was used to determine the hazard ratio.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.379","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.366","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.577","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.460","statisticalComment":"Unstratified analysis","statisticalMethod":"Log Rank"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","statisticalComment":"Unstratified analysis","statisticalMethod":"Peto-Peto-Prentice"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","statisticalComment":"Stratified analysis:Strata were chemotherapy selected, prior anti-angiogenic therapy, and platinum-free interval.","statisticalMethod":"Peto-Peto-Prentice"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.10","upperLimit":"3.75","value":"3.4"},{"groupId":"OG001","lowerLimit":"5.62","upperLimit":"7.79","value":"6.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"description":"PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the RECIST criteria (for participants with measurable disease), and for those with non-measurable disease presence or absence of lesions was noted. Time from randomization to occurrence of disease progression or death was measured in months. An event was defined as the earliest progressive disease or death that occurred on or before the cutoff date (14 November 2011), regardless of start of nonprotocol specified anti-cancer therapy or the bevacizumab monotherapy. Disease progression was assessed by investigator according to RECIST or by symptom deterioration, and could not be declared on the basis of rising cancer antigen 125 (CA125) levels alone. Kaplan-Meier methodology was used. 95% CI for median was computed using the method of Brookmeyer and Crowley.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 q4w OR topotecan 4 mg/m\\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\\^2 dose could have been administered over 30 minutes on Days 1-5 q3w) OR PLD 40 mg/m\\^2 as a 1 mg/min infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion). Depending on chosen chemotherapy, pre-medication was implemented according to local practices.","id":"OG000","title":"Chemotherapy"},{"description":"Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 q4w OR topotecan 4 mg/m\\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\\^2 dose could have been administered over 30 minutes on Days 1-5 q3w) OR PLD 40 mg/m\\^2 as a 1 mg/min infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion). Depending on chosen chemotherapy, pre-medication was implemented according to local practices. The chosen chemotherapy was combined with bevacizumab 10 mg/kg IV q2w (or bevacizumab 15 mg/kg q3w if used in combination with topotecan 1.25 mg/m\\^2 on Days 1-5 on a q3w schedule). The initial bevacizumab infusion was over 90 minutes, with subsequent infusions over 60 minutes and then 30 minutes, as tolerated.","id":"OG001","title":"Chemotherapy + Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"ITT Population; only participants with an event of progression or death were included in the analysis","reportingStatus":"POSTED","timeFrame":"Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011","title":"Progression Free Survival (PFS; Data Cutoff 14 November 2011)","type":"PRIMARY","unitOfMeasure":"months"}